Lawitz 2008

Methods	Randomised clinical trial
Participants	33 participants Sex: 28 men, 5 women Mean age: not described. Inclusion criteria: treatment‐naive and treatment‐experienced noncirrhotic participants,18‐55 years old, with high viral load, genotype 1, chronic HCV infection.
Interventions	Experimental group: oral 125 mg, 600 mg of MK‐7009 once daily for 8 days or 25 mg, 75 mg, 250 mg, or 500 mg of MK‐7009 twice daily for 8 days. Control group: placebo.
Outcomes	HCV RNA, safety assessment.
Notes	We emailed Lawitz and colleagues on 26 April 2016 for additional information on random, blinding, missing data, protocol, data, participants' characteristics, funding, number of participants in placebo/exp group but reply not received yet.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Described as placebo‐blinded, but it was not described how blinding was performed
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Described as placebo‐blinded, but it was not described how blinding was performed
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not described
Selective reporting (reporting bias)	Unclear risk	No protocol could be obtained
Vested‐interest bias	High risk	Several authors worked for several pharmaceutical companies
Other bias	Low risk	The trial appeared to be free of other components that could put it at risk of bias